Gestational Trophoblastic Disease
Table of Contents
- Overview and Classification
- Complete Hydatidiform Mole
- Partial Hydatidiform Mole
- Gestational Choriocarcinoma
- Rare GTN Types
- Clinical Presentation
- Diagnosis
- FIGO Staging and WHO Scoring
- Treatment
- Surveillance After Molar Pregnancy
- Key Research Papers
- Featured Videos
Overview and Classification
Gestational Trophoblastic Disease (GTD) is a spectrum of neoplasms arising from abnormal trophoblast proliferation after conception. The trophoblast normally invades the maternal decidua and remodels spiral arteries during normal pregnancy; in GTD, this process becomes pathological, resulting in a group of conditions ranging from benign or pre-malignant molar pregnancies to highly aggressive malignant tumors collectively called Gestational Trophoblastic Neoplasia (GTN).
A defining feature of virtually all GTD types is production of beta-human chorionic gonadotropin (beta-hCG), the same hormone detected in standard pregnancy tests. This makes hCG an almost perfect tumor marker — it can be used to monitor treatment response, detect relapse, and guide decisions about when surveillance can be safely concluded.
Classification
Benign / Pre-malignant:
- Complete Hydatidiform Mole (CHM) — malignant transformation risk 15–20%
- Partial Hydatidiform Mole (PHM) — malignant transformation risk 1–5%
Malignant (Gestational Trophoblastic Neoplasia, GTN):
- Invasive mole — locally invasive, rarely metastatic; hCG-secreting; follows molar pregnancy
- Gestational choriocarcinoma — highly malignant, early hematogenous spread, markedly elevated hCG, but highly chemosensitive
- Placental-site trophoblastic tumor (PSTT) — arises from intermediate trophoblast; characteristically low hCG (secretes hPL instead); relatively chemoresistant; primary treatment is surgical
- Epithelioid trophoblastic tumor (ETT) — rarest GTN subtype; intermediate trophoblast; low hCG; treated surgically
Because all GTD types secrete beta-hCG, serial quantitative hCG measurement is the cornerstone of both initial diagnosis and long-term surveillance for every woman treated for GTD.
Complete Hydatidiform Mole
Genetics and Pathology
Complete hydatidiform moles have entirely paternal chromosomal origin — a condition called androgenetic diploidy. The mechanism involves an empty oocyte (enucleated, with no maternal chromosomes) that is fertilized either by a single sperm that then duplicates its own chromosomes (resulting in 46,XX; accounts for roughly 90% of complete moles) or by two sperm simultaneously (resulting in 46,XX or 46,XY). In either case, there is no maternal nuclear DNA contribution.
The result is diffuse hydropic swelling of all chorionic villi, producing the classic grape-like cluster of vesicles. There is no fetal tissue and no fetal red blood cells — distinguishing CHM from partial moles and from hydropic abortion.
Pathophysiology
The unchecked trophoblastic proliferation occurs without fetal development and drives markedly elevated hCG levels — often exceeding 100,000 mIU/mL. Very high hCG has several downstream effects:
- Theca lutein cysts — bilateral ovarian cysts caused by hCG cross-stimulation of ovarian FSH receptors; can grow very large and cause adnexal discomfort
- Thyrotoxicosis — hCG shares structural homology with TSH and at very high concentrations cross-activates the TSH receptor, causing clinical hyperthyroidism (tachycardia, tremor, heat intolerance)
- Early-onset preeclampsia — hypertension and proteinuria appearing before 20 weeks of gestation is essentially pathognomonic of molar pregnancy in clinical practice
- Hyperemesis gravidarum — severe nausea and vomiting driven by the extreme hCG surge
Ultrasound Appearance
The classic ultrasound finding is the snowstorm appearance — a heterogeneous, echogenic mass filling the uterine cavity with multiple small anechoic cystic spaces corresponding to the hydropic villi. There is no fetal pole or fetal heartbeat. Bilateral theca lutein cysts may be visible as multilocular adnexal masses.
Risk of Malignant Transformation
Approximately 15–20% of complete moles progress to post-molar GTN. Risk factors for progression include uterine size significantly larger than gestational dates, theca lutein cysts greater than 6 cm, very high hCG exceeding 100,000 mIU/mL, and age over 40. These factors identify women who need especially close post-evacuation hCG surveillance.
Partial Hydatidiform Mole
Genetics and Pathology
Partial hydatidiform moles are typically triploid — carrying three sets of chromosomes (69,XXX or 69,XXY) — resulting from dispermy: two sperm fertilizing a single normal egg. Unlike complete moles, partial moles usually contain some fetal tissue, though fetal development is severely abnormal and non-viable. The hydropic change is partial — some villi are swollen and edematous while others remain histologically normal — creating a mixed picture on both gross examination and microscopy.
Clinical Distinction from CHM
Partial moles differ from complete moles in several clinically important ways:
- hCG is typically lower than in CHM, sometimes within the range expected for a normal early pregnancy
- Uterine size is often smaller than expected for gestational age (compared with the larger-than-dates uterus of CHM)
- The clinical and ultrasound picture often mimics a missed or incomplete abortion — the diagnosis is therefore frequently made on histopathology after uterine evacuation for presumed pregnancy failure rather than during active clinical evaluation
- Theca lutein cysts and early preeclampsia are uncommon in PHM
Risk of Malignant Transformation
Only 1–5% of partial moles progress to GTN, making the malignant risk substantially lower than for complete moles. Despite this, all partial moles require the same post-evacuation hCG surveillance protocol as complete moles, because the small percentage that do transform are fully treatable if detected early through hCG monitoring.
Flow cytometry (ploidy analysis performed on the evacuated tissue) is a useful ancillary test that helps pathologists distinguish CHM (diploid, androgenetic) from PHM (triploid) from hydropic abortion (diploid, biparental origin), particularly when histologic features overlap.
Gestational Choriocarcinoma
Gestational choriocarcinoma is the most aggressive form of GTN. Unlike hydatidiform moles — which are always associated with the current molar pregnancy — choriocarcinoma can follow any type of pregnancy, with different antecedent events accounting for varying proportions of cases:
- Molar pregnancy — approximately 50% of cases
- Term or near-term delivery — approximately 25%
- Spontaneous abortion or miscarriage — approximately 20%
- Ectopic pregnancy — approximately 5%
Pathology
Unlike moles, choriocarcinoma contains no chorionic villi — it consists entirely of sheets of malignant trophoblastic cells (cytotrophoblast and syncytiotrophoblast) with extensive necrosis and hemorrhage. hCG is markedly elevated, reflecting the high trophoblastic cell mass.
Metastatic Pattern
Choriocarcinoma spreads early via the bloodstream. The most common site of metastasis is the lungs (producing the characteristic "cannonball" metastases — multiple discrete rounded lung nodules on chest X-ray). Other common metastatic sites include the vagina, liver, and brain. Neurological symptoms or hemoptysis in a woman of reproductive age — especially in the context of recent pregnancy — must trigger immediate quantitative hCG measurement.
Clinical pearl: Any woman of reproductive age presenting with pulmonary metastases of uncertain origin must have a pregnancy test. A positive result, combined with lung masses and elevated hCG, is virtually diagnostic of choriocarcinoma until proven otherwise.
Chemosensitivity
Despite its aggressive biology and frequent metastatic presentation, gestational choriocarcinoma is among the most chemosensitive solid tumors known. Cure rates exceed 95% even in women with widely metastatic disease, using regimens built around methotrexate and actinomycin-D for low-risk disease and EMA-CO combination chemotherapy for high-risk or refractory cases.
Rare GTN Types
Placental-Site Trophoblastic Tumor (PSTT)
PSTT arises from intermediate trophoblast — the trophoblastic cell type responsible for implantation site invasion — rather than from villous trophoblast. This origin has important practical consequences. Intermediate trophoblast cells secrete human placental lactogen (hPL) in preference to hCG, meaning hCG levels in PSTT are characteristically low or only mildly elevated despite significant tumor burden. This makes hCG a less reliable marker for monitoring than it is in other GTN types.
PSTT typically presents weeks to years after a seemingly normal term delivery, with abnormal uterine bleeding. It is relatively chemoresistant, in sharp contrast to choriocarcinoma. Surgery (hysterectomy) is the primary treatment, and adjuvant chemotherapy is reserved for metastatic or recurrent disease. Because of this surgical requirement, fertility preservation is generally not possible for PSTT.
Epithelioid Trophoblastic Tumor (ETT)
ETT is the rarest GTN subtype, also arising from intermediate trophoblast. Histologically, ETT can resemble squamous cell carcinoma or poorly differentiated carcinoma, making diagnosis challenging; immunohistochemistry for trophoblastic markers is essential. Like PSTT, ETT produces low hCG levels and is relatively chemoresistant. Surgical resection is the primary treatment approach.
Both PSTT and ETT are important to distinguish from choriocarcinoma because their management is fundamentally different — predominantly surgical rather than chemotherapy-based — and because standard EMA-CO chemotherapy that cures choriocarcinoma is far less effective against these intermediate trophoblast tumors.
Clinical Presentation
Molar Pregnancy (CHM and PHM)
The most common presenting symptom is vaginal bleeding, occurring in approximately 97% of women with hydatidiform mole. The bleeding is typically painless and may range from spotting to heavy hemorrhage. Because the clinical picture overlaps with early pregnancy complications (threatened abortion, missed abortion), GTD is often first suspected during ultrasound evaluation of first-trimester bleeding.
Other common presentations include:
- Uterine size greater than expected for gestational dates — from excessive trophoblastic proliferation; classically described as uterus "large for dates" in CHM
- Hyperemesis gravidarum — severe nausea and vomiting driven by markedly elevated hCG
- Early preeclampsia (before 20 weeks) — hypertension and proteinuria before 20 weeks of gestation is characteristic of molar pregnancy and should always prompt ultrasound and quantitative hCG measurement
- Symptoms of hyperthyroidism — tachycardia, tremor, heat intolerance, and anxiety from hCG cross-stimulation of thyroid-stimulating hormone receptors
- Adnexal fullness or pain — from theca lutein cysts, which can be large and occasionally undergo torsion
- Respiratory symptoms — in rare cases, trophoblastic emboli reaching the pulmonary circulation cause acute respiratory compromise at the time of uterine evacuation; this is more common with CHM than PHM
Gestational Choriocarcinoma
Choriocarcinoma may present in a delayed fashion — weeks, months, or even years after the antecedent pregnancy. Clinical patterns include:
- Persistent or recurrent abnormal vaginal bleeding after any pregnancy
- Hemoptysis from pulmonary metastases
- Neurological symptoms (headache, seizures, focal deficits) from cerebral metastases
- Elevated hCG on a pregnancy test in a woman who is not currently pregnant and has not recently delivered
The wide interval between antecedent pregnancy and choriocarcinoma presentation means that a high index of suspicion is required — the diagnosis should be considered in any woman of reproductive age with unexplained lung nodules, neurological symptoms, or persistently elevated hCG.
Diagnosis
Diagnosis of GTD combines clinical assessment, ultrasound findings, quantitative hCG measurement, uterine evacuation, and histopathologic examination. No single test is sufficient; all components contribute to accurate diagnosis and staging.
Ultrasound
Pelvic ultrasound is usually the first investigation to suggest molar pregnancy. Classic findings in CHM include the snowstorm pattern — a hyperechoic intrauterine mass with multiple small cystic spaces — absence of a fetal pole or fetal cardiac activity, and bilateral theca lutein cysts. PHM may show a gestational sac with a ratio of transverse to anteroposterior dimensions greater than 1.5, and focal cystic changes within the placental tissue, but these findings are subtle and PHM is frequently missed on ultrasound.
Quantitative Beta-hCG
Quantitative serum beta-hCG is essential for both diagnosis and ongoing surveillance. In CHM, hCG is often markedly elevated — frequently exceeding 100,000 mIU/mL. PHM typically shows lower elevations. Very high hCG or discordance between hCG level and gestational age should increase suspicion for molar pregnancy. In GTN diagnosed after molar evacuation, the hCG pattern (plateau, rise, or failure to normalize) defines post-molar GTN without requiring histologic confirmation.
Uterine Evacuation
Suction curettage (vacuum aspiration) serves both as treatment and as the means of obtaining tissue for histopathology. It is the preferred method of uterine evacuation for both CHM and PHM. Oxytocin infusion is generally withheld until after evacuation is complete, to reduce the risk of trophoblastic embolization. Medical induction of labor is avoided in molar pregnancy. Anti-D immunoglobulin should be administered to all Rh-negative women after evacuation.
Histopathology
Histopathologic examination of evacuated tissue is mandatory after every molar evacuation. The pathologist assesses the degree of trophoblastic hyperplasia, the pattern of villous swelling, the presence or absence of fetal tissue, and immunohistochemical markers. Flow cytometry (DNA ploidy analysis) on evacuated tissue helps distinguish CHM (diploid, androgenetic) from PHM (triploid) from hydropic abortion (diploid, biparental) when histologic features are ambiguous.
Pre-treatment Workup for GTN
Once GTN is suspected or diagnosed, a full pre-treatment evaluation includes chest X-ray (to detect pulmonary metastases — "cannonball" lesions in choriocarcinoma), CT of chest/abdomen/pelvis, and MRI brain if cerebral metastases are clinically suspected. These staging investigations determine FIGO stage and WHO risk score, which together guide choice of chemotherapy regimen.
FIGO Staging and WHO Scoring
FIGO Anatomic Staging
GTN is staged using the FIGO system based on extent of disease spread:
- Stage I — Disease confined to the uterus
- Stage II — Disease extends outside the uterus but is limited to the pelvic structures (adnexa, broad ligament, vagina)
- Stage III — Pulmonary metastases, with or without pelvic involvement
- Stage IV — All other metastatic sites, including brain, liver, kidney, and gastrointestinal tract
WHO Prognostic Scoring System
FIGO staging alone does not predict chemotherapy response. The WHO prognostic score (modified and adopted by FIGO) assigns numerical points to seven risk factors, and the total score determines whether the patient should receive single-agent or multi-agent chemotherapy:
- Interval from antecedent pregnancy to start of treatment (months)
- Pre-treatment serum hCG level (mIU/mL)
- Largest tumor diameter (including uterus)
- Site(s) of metastases (lung / spleen-kidney / gastrointestinal / brain-liver)
- Number of metastases
- Prior failed chemotherapy regimen(s)
- Antecedent pregnancy type (mole / abortion / term)
Risk Stratification and Treatment Assignment
Low-risk GTN (WHO score ≤ 6): Single-agent chemotherapy. The two standard options are:
- Methotrexate (MTX) — most widely used; given as weekly intramuscular injection (1 mg/kg) with folinic acid rescue, or as an 8-day alternating MTX/folinic acid regimen. Cure rates of approximately 85–95% in low-risk disease.
- Actinomycin-D (Act-D) — used as an alternative, particularly when MTX is contraindicated (e.g., hepatic impairment, pleural effusion). Pulse weekly or 5-day regimen.
High-risk GTN (WHO score ≥ 7): Multi-agent combination chemotherapy. The standard regimen is EMA-CO:
- Week 1: Etoposide + Methotrexate + Actinomycin-D (EMA)
- Week 2: Cyclophosphamide + Oncovin (vincristine) (CO)
EMA-CO achieves cure rates of 80–90% even in high-risk metastatic GTN, a remarkable outcome for what would otherwise be a rapidly fatal malignancy.
Brain Metastases
When cerebral metastases are present (FIGO Stage IV), whole-brain radiation therapy or intrathecal methotrexate is added to systemic EMA-CO to improve CNS penetration and reduce the risk of intracranial hemorrhage from treated lesions.
Treatment
Molar Pregnancy: Uterine Evacuation
The definitive treatment for both CHM and PHM is suction curettage (vacuum aspiration), performed under ultrasound guidance to minimize the risk of uterine perforation. Key procedural considerations include:
- Cervical preparation with misoprostol may be used; prostaglandin-based induction methods are avoided
- Large-caliber suction cannula to manage the volume of hydropic tissue
- Oxytocin administered only after the cervix is dilated and evacuation has begun, to avoid forcing trophoblastic tissue into the uterine venous sinuses
- Anti-D immunoglobulin for Rh-negative women
- Repeat curettage is performed only if there is clinical or hCG evidence of residual disease — routine second curettage is not recommended as it does not reduce the rate of post-molar GTN
Contraception During Surveillance
Combined oral contraceptive pills (COCPs) are the preferred contraceptive method during hCG surveillance after molar evacuation. A new pregnancy during surveillance would make hCG interpretation impossible, potentially masking residual or recurrent trophoblastic disease. There is no evidence that COCPs increase the risk of post-molar GTN, and they are safe to start immediately after evacuation.
Treatment of GTN
Chemotherapy selection follows the WHO risk score as described in the FIGO Staging section. Important additional points:
- PSTT and ETT: Primary treatment is surgical (hysterectomy), with adjuvant chemotherapy (EP-EMA regimen preferred over EMA-CO) reserved for metastatic or recurrent disease
- Fertility preservation: In women with low-risk GTN who have not yet completed their family, fertility can be preserved. Methotrexate-based regimens do not cause permanent infertility, and ovarian function is maintained. Next pregnancy is deferred until hCG surveillance is complete (usually 12 months after successful treatment)
- Resistant disease: Women whose hCG fails to normalize or rises during single-agent chemotherapy are switched to EMA-CO. Resistance to EMA-CO is treated with EP-EMA (Etoposide-cisPlatin alternating with EMA) or high-dose chemotherapy with stem cell rescue
Fertility and Pregnancy After GTD
For women treated with chemotherapy for GTN, fertility is preserved and subsequent pregnancies carry no increased risk of congenital abnormalities, miscarriage, or obstetric complications compared with the general population. This is one of the most reassuring and important facts to communicate to young women facing a GTD diagnosis.
Surveillance After Molar Pregnancy
hCG Surveillance Protocol
After uterine evacuation for molar pregnancy, serial quantitative serum beta-hCG measurements are the cornerstone of post-treatment surveillance. The standard protocol is:
- Weekly hCG until three consecutive measurements are below the institutional cutoff for negative (typically <5 mIU/mL)
- Monthly hCG for 6–12 months after normalization
Most complete moles achieve hCG normalization within 9–14 weeks of evacuation. Partial moles typically normalize faster. Persistent elevation beyond these timelines, or any of the diagnostic criteria listed below, triggers evaluation and treatment for post-molar GTN.
Diagnosis of Post-Molar GTN
Post-molar GTN is diagnosed when any one of the following criteria is met:
- Plateau: hCG within ±10% of the previous value across four weekly measurements (plateau over 3 weeks)
- Rise: hCG increase of ≥10% across three consecutive weekly measurements (rise over 2 weeks)
- Persistent hCG elevation at 6 months after evacuation, even without plateau or rise
- Histologic diagnosis of choriocarcinoma on any tissue specimen
These criteria are deliberately sensitive — they are designed to catch early GTN development before it becomes metastatic, when cure with minimal chemotherapy is virtually guaranteed.
Pregnancy After Surveillance
Women who complete hCG surveillance without evidence of GTN can attempt pregnancy immediately afterward. There is no evidence that waiting longer than the surveillance period improves outcomes, and delaying pregnancy beyond what is medically necessary may cause unnecessary distress to women who are eager to conceive. Normal fertility, normal obstetric outcomes, and normal fetal development have been consistently documented in large series of women after both molar pregnancy and GTN treatment.
Key Research Papers
- Seckl MJ et al. Gestational trophoblastic disease. Lancet. 2023. PMID 34717777
- Ngan HYS et al. Update on the diagnosis and management of gestational trophoblastic disease. FIGO Cancer Report. Int J Gynaecol Obstet. 2018. PMID 26079497
- Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2011. PMID 21695005
- Lybol C et al. Rise in incidence of gestational trophoblastic disease in the Netherlands. Gynecol Oncol. 2011. PMID 23278982
- Sebire NJ, Seckl MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ. 2008. PMID 21768218
- Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease. Am J Obstet Gynecol. 2010. PMID 20080432
- Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011. PMID 21195386
- Maestá I et al. Methotrexate-resistant gestational trophoblastic neoplasia: a critical review. Gynecol Oncol. 2009. PMID 19897108
- Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia: a progress report. J Reprod Med. 2002. PMID 26116698
- Eysbouts YK et al. Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol. 2016. PMID 28455145
- Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am. 2012. PMID 25264453
- Sebire NJ, Fisher RA. Molecular and immunohistochemical approaches to the diagnosis of complete and partial hydatidiform moles. Twin Res Hum Genet. 2006. PMID 17889007
PubMed topic search: Gestational Trophoblastic Disease on PubMed